Anti-inflammatory Effect of Aqueous Extract of Cassia fistula in Acetic Acid Model of Colitis in Rats

Document Type : Research Paper

Authors

1 Department of Pharmacology, School of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Department of Pharmacognosy, School of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Herbal Medicines Research Center, School of Pharmacy, Shahid Sadoughi University of Medical Science Health Services, Yazd, Iran

Abstract

Considering the beneficial effects of herbal medicine in comparison with synthetic drugs and also the recommendation of Iranian medical scholars on the use of Cassia fistula L. in gastrointestinal inflammations, in this study the effect of aqueous extract of C. fistula fruit on the histopathological improvement of ulcerative colitis was evaluated in rats. In this study, 30 rats with a weight range of 250-300 g and about 2 months were used. Ulcerative colitis was induced by acetic acid in rats, then the animals were treated orally with normal saline, sulfasalazine (360 mg/kg), or aqueous extract of C. fistula (600 and 800 mg/kg) once daily for 5 days. The animals were then sacrificed and their colons were evaluated macroscopically, histopathologically, and for myeloperoxidase (MPO) activity and weight. The severity and extent of colonic inflammation in animals receiving 400 and 800 mg/ml of C. fistula extract showed a significant decrease compared to those receiving normal saline (P< 0.05). A decrease in colon weight was observed in the group of animals receiving a concentration of 800 mg/ml of the extract. C. fistula aqueous extract did not show any effect in reducing the activity of the MPO enzyme.

Keywords

Main Subjects

References

  1. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases. 2006;12(suppl_1):S3-S9.
  2. Wang J., Fu Y.X. Tumor necrosis factor family members and inflammatory bowel disease. Immunological reviews. 2005;204(1):144-55.
  3. Colitis–Pathophysiology U. Inflammatory bowel disease part I: ulcerative colitis–pathophysiology and conventional and alternative treatment options. Alternative Medicine Review. 2003;8(3):247-83.
  4. Hawkins H.P. An address on the natural history of ulcerative colitis and its bearing on treatment. British Med. J. 1909;1(2517):765.
  5. Kathleen A. Head N., Jurenka J.S. Inflammatory bowel disease part I: ulcerative colitis–pathophysiology and conventional and alternative treatment options. Alternative Medicine Review. 2003;8(3):247-83.
  6. Taherkhani R., Ahmadi B., Farshad Pour F., Esmaeilizadeh M., Dolatshahi M., Makvandi M., et al. Epidemiologic Characteristics and Frequency of Anatomical Pattern of Ulcerative Colitis in Patients Referred to Imam Khomeini Hospital During Years 2007 to 2011. Jundishapur Scientific Med. J. 2014;13(3):276-81.
  7. Bernstein C.N., Wajda A., Svenson L.W., MacKenzie A., Koehoorn M., Jackson M., et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. American J. Gastroenterology. 2006;101(7):1559-68.
  8. Erik B., Van Wyk M.W. Medicinal plants of the world. Briza Publications. 2009.
  9. Khan W., Subhan S., Shams D.F., Afridi S.G., Ullah R., Shahat A.A., et al. Antioxidant Potential, Phytochemicals Composition, and Metal Contents of Datura alba. Biomed. Res. Int. 2019;2019:2403718-.
  10. Fabia R., Willen R., Ar’Rajab A., Andersson R., Ahren B., Bengmark S. Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis. European Surgical Res. 1992;24(4):211-25.
  11. Noronha-Blob L., Lowe V.C., Muhlhauser R.O., Burch R.M.J.G. NPC 15669, an inhibitor of neutrophil recruitment, is efficacious in acetic acid-induced colitis in rats. 1993;104(4):1021-9.
  12. MacPherson B., Pfeiffer C.J.D. Experimental production of diffuse colitis in rats. 1978;17(2):135-50.
  13. Chou T.C. Anti‐inflammatory and analgesic effects of paeonol in carrageenan‐evoked thermal hyperalgesia. British J. Pharma. 2003;139(6):1146-52.
  14. Kappelman M.D., Moore K.R., Allen J.K., Cook S.F. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Digestive Diseases and Sci. 2013;58(2):519-25.
  15. Murad H.A., Abdallah H.M., Ali S.S. Mentha longifolia protects against acetic-acid induced colitis in rats. J. Ethnopharmacology. 2016;190:354-61.
  16. Ali M.A. Cassia fistula Linn: a review of phytochemical and pharmacological studies. Int. J. Pharm. Sci. Res. 2014;5(6):2125-30.
  17. Rahmani A.H. Cassia fistula Linn: Potential candidate in the health management. Pharmacognosy Res. 2015;7(3):217.
  18. Yamada T., Marshall S., Specian R..D., Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology. 1992;102(5):1524-34.
  19. Kumar M.S., Sripriya R., Raghavan H.V., Sehgal P.K. Wound healing potential of Cassia fistula on infected albino rat model. J. Surgical Res. 2006;131(2):283-9.
  20. Rahimi R., Shams-Ardekani M.R., Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J. Gastroenterology: WJG. 2010;16(36):4504.
Journal of Medicinal plants and By-Products
Volume 13, Special
November 2024
Pages 870-877

Files

Share

How to cite

Statistics